Rituximab for the first-line treatment of stage III-IV follicular lymphoma - guidance (TA243)

National Institute for Health and Care Excellence - NICE
Publication date:
25 January 2012


Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.

This guidance replaces NICE technology appraisal guidance 110.

The recommendations also apply to rituximab biosimilar products that have a marketing authorisation allowing the use of the biosimilar for the same indication.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in August 2014. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.